Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval of ZEPOSIAÂ ozanimod for the Treatment of Adult Patients with Relapsing Remitting Multiple Sclerosis with Active Disease

Bristol Myers Squibb NYSEBMY today announced that the Committee for Medicinal Products for Human Use CHMP of the European Medicines Agency has adopted a positive opinion for ZEPOSIAÂ ozanimod for the treatment of adult patients with relapsing remitting mul...